Home   >  
PI3K/Akt/mTOR
  >  
AKT
  >   AKT inhibitor
AKT inhibitor Chemical Structure

AKT inhibitor

Data Sheet For research use only. Not for human use.
Cat. No. :BCP16893CAS No. :1004990-28-6Purity:98%
 Tel: 0086-13026320035   or   orders@biochempartner.com
Real-Time Inquiry ×

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Inquiry Online ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Bulk Inquiry ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

  • Chemical Properties&Biological Activity
CAS No. 1004990-28-6 Cat. No. BCP16893
Name AKT inhibitor
Synonyms AKT protein kinase inhibitor;
SMILES
Chemical Name
Formula C20H22F2N6O M. Wt 400.43
Purity 98% Storage Store at 4-8°C
Description In vitro: AKT inhibitor binds deeply into the active pocket of PKBα, creating favorably hydrophobic interactions with more residues than that with PKA.[1] AKT inhibitor achieves 900-fold selectivity for Akt over PKA, presumably because of the increased steric demand of the ethyl core substituent being better tolerated in Akt than in PKA. AKT inhibitor is chosen as the most promising molecule to advance to clinical development. in vivo: AKT inhibitor is well absorbed (F = 54%) in dog pharmacokinetic studies (oral at 2 mg/kg, iv at 1.2 mg/kg), with moderate clearance (11.6 mL/min/kg) and volume of distribution (4.8 L/kg), and a half-life of 4.4 h. AKT inhibitor is subsequently evaluated for modulation of Akt in tumors53 and in multiple in vivo mouse models of antitumor efficacy. AKT inhibitor is active in a PC3 prostate carcinoma xenograft experiment, with 75% TGI observed at 100 mg/kg b.i.d. dosing for 10 days. In a colorectal carcinoma (Colo205) xenograft study, AKT inhibitor produces
  • Quality Control&Technical Support
In the process of purchasing and using Biochempartner products, you can consult us if you have any problems: orders@biochempartner.com. We will try our best to solve all your doubts.

Recommend Products

More >

Tags:AKT inhibitor supplier,AKT inhibitor purchase,AKT inhibitor manufacturer,AKT inhibitor distributor,AKT inhibitor cost,AKT inhibitor buy,AKT inhibitor for sale

0086-13720134139